Form 8-K

8-K — Zura Bio Ltd

Accession: 0001104659-26-047784

Filed: 2026-04-23

Period: 2026-04-20

CIK: 0001855644

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — tm2612540d1_8k.htm (Primary)

EX-10.1 — EXHIBIT 10.1 (tm2612540d1_ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2612540d1_8k.htm · Sequence: 1

false

0001855644

2026-04-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

Warrants [Member]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,

D.C. 20549

Form

8-K

Current

Report

Pursuant

to Section 13 or

15(d)

of the Securities Exchange Act of 1934

April 20, 2026

Date of Report (Date of earliest event reported)

Zura Bio Limited

(Exact name of registrant as specified in its charter)

Cayman Islands

001-40598

98-1725736

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

(Address of principal

executive offices,

including zip code)

(702) 825-9872

(Registrant’s telephone

number, including area code)

(Former name or former address,

if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written

communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name

of each exchange on which

registered

Class A Ordinary Shares, par value $0.0001 per share

ZURA

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Transition of Chief Financial Officer

On April 20, 2026, Eric Hyllengren,

the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, was separated from the Company.

Mr. Hyllengren’s separation was not related to the Company’s financial or operating results or to any disagreements regarding

the Company’s operations or financial or reporting practices.

In connection with his separation,

the Company and Mr. Hyllengren entered into a Separation Agreement on April 21, 2026. Mr. Hyllengren will receive severance

payments in an amount equal to three months of his base salary and reimbursement for COBRA premiums for up to six months. All payments

and benefits provided under the Separation Agreement are contingent upon the effectiveness of, and Mr. Hyllengren’s continued

compliance with, the Separation Agreement, and are subject to payments and benefits available through other employment or eligibility.

The foregoing description

of the Separation Agreement is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full

text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

Appointment of Principal Accounting Officer

and Principal Financial Officer

Also on April 20, 2026, the

Board appointed Marlyn Mathew, the Company’s Vice President, Finance and Accounting, as the Company’s principal accounting

and principal financial officer (the “Appointment”). In connection with the Appointment, the Board approved an increased annual

base salary for Ms. Mathew of $366,415.

Ms. Mathew, 42, serves as

the Company’s Vice President, Finance and Accounting, a role she has held since June 2022. Prior to joining the Company, Ms. Mathew

was Controller at Immunovant from 2019 to May 2022, having previously served as Assistant Controller from 2018 to 2019. Ms. Mathew holds

a Bachelor of Science in Accounting from Rutgers University.

Ms. Mathew is not party to

any arrangement or understanding with any other person pursuant to which she was appointed as an officer, nor is she party to any transactions

required to be disclosed pursuant to Item 404(a) of Regulation S-K involving the Company. There are no family relationships between Ms.

Mathew and any of the Company’s directors and executive officers.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

10.1+

Separation Agreement, by and between the Company

and Eric Hyllengren, signed April 21, 2026

104

Cover Page Interactive Data

File (embedded within the Inline XBRL document)

+ Indicates management contract

or compensatory plan.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZURA BIO LIMITED

Date: April 23, 2026

By:

/s/ Kim Davis

Kim Davis

Chief Operating Officer, Chief Legal Officer and Corporate Secretary

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2612540d1_ex10-1.htm · Sequence: 2

Exhibit 10.1

April 17, 2026

Eric Hyllengren

Via Email

Dear Eric:

This letter sets forth the terms of the separation

agreement (the “Agreement”) that Zura Bio Inc. (the “Company”) is offering to you to aid in your

employment transition.

Separation. Your last day of work with the Company and your employment termination

date will be April 20, 2026 (the “Separation Date”). Between April 17, 2026, and the Separation Date, you will not

be expected, permitted, or required to report to work or perform any services for the Company, except upon reasonable request of the Company.

Accrued Salary and Paid Time Off. On the Separation Date, the Company will pay

you all accrued salary and all accrued and unused paid time off earned through the Separation Date, subject to standard payroll deductions

and withholdings. You are entitled to this payment by law.

Severance Benefits. Although the Company has no obligation to do so, if you

timely sign this Agreement and comply with your obligations under it (collectively, the “Severance Preconditions”),

then the Company will provide you with the following “Severance Benefits”:

(a)       Severance

Payment. Company will pay you, as severance, up to the equivalent of three (3) months of your base salary in effect as of the Separation

Date, subject to standard payroll deductions and withholdings. This amount will be paid in the form of salary continuation starting on

the Company’s first regularly scheduled payroll date that is within fifteen (15) calendar days after the Effective Date (as defined

in Section 8(c) of this Agreement); provided, however, that such salary continuation payments shall immediately cease upon

the date you commence employment or self-employment with any other person or entity. You agree to promptly notify the Company in writing

if you obtain such employment or self-employment during the salary continuation period.

(b)       COBRA

Premiums. As an additional Severance Benefit under this Agreement, provided that you satisfy the Severance Preconditions set forth

in this agreement and timely elect continued coverage under COBRA, then the Company shall reimburse you for the COBRA premiums to continue

your health insurance coverage (including coverage for eligible dependents, if applicable) through the period (the “COBRA Premium

Period”) starting on the Separation Date and ending on the earliest to occur of: (i) October 31, 2026; (ii) the date you become

eligible for group health insurance coverage through a new employer or a family member’s employer; or (iii) the date you cease to

be eligible for COBRA coverage for any reason (the “COBRA Severance Benefit”). You must timely pay your COBRA premiums,

and then provide documentation to the Company, to obtain reimbursement for your COBRA premiums under this Section 3. In the event you

become covered under another group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you must immediately

notify the Company in writing. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that the

payment of the COBRA Severance Benefit would result in a violation of applicable law (including, but not limited to, Section 105(h) of

the Internal Revenue Code of 1986, as amended, Section 2716 of the Public Health Service Act, or any statute or regulation of similar

effect), then, provided you remain eligible for reimbursement in accordance with this section, in lieu of providing the COBRA Severance

Benefit, the Company will instead pay you on the last day of each remaining month of the COBRA Premium Period, a fully taxable cash payment

equal to the COBRA Severance Benefit for that month, subject to applicable tax withholdings for the remainder of the COBRA Premium Period.

You may, but are not obligated to, use this taxable payment to pay for medical expenses, including COBRA premiums.

Page 2

Credit Waiver. As an additional Severance Benefit under this Agreement, provided that you satisfy the Severance Preconditions set

forth in this Agreement, the Company agrees to waive its right to require you to return or transfer approximately $15,000 in airline travel

credits currently held in your name that were accrued in connection with Company business travel.

Health Insurance. Your participation in the Company’s group health insurance

plan will end on the last day of the month in which the Separation Date occurs. To the extent provided by the federal COBRA law or, if

applicable, state insurance laws, and by the Company’s current group health insurance policies, you will be eligible to continue

your group health insurance benefits at your own expense following the Separation Date, subject to Section 3(b). Later, you may be able

to convert to an individual policy through the provider of the Company’s health insurance, if you wish. You will be provided with

a separate notice describing your rights and obligations under COBRA and a form for electing COBRA coverage.

Stock Options. Under the terms of your stock option agreement and the applicable

plan documents, vesting of your stock options will cease as of the Separation Date. As of the Separation Date, you do not have any vested

stock options under any Company stock option agreement and all stock options awarded to you will be forfeited on the Separation Date.

Other Compensation or Benefits. You acknowledge that, except as expressly provided

in this Agreement, you have not earned and will not receive from the Company any additional compensation (including base salary, bonus,

incentive compensation, or equity), severance, or benefits before or after the Separation Date, with the exception of any vested right

you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account).

Expense Reimbursements. You agree that, within thirty (30) days after the Separation

Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred on your Company

credit card through the Separation Date, if any, to allow Company to complete internal documentation. Other than the airline travel credits

specified in Section 3(c), any expenses charged to a Company credit card that were not approvable pursuant to a Company policy shall be

reimbursed by you within thirty (30) days of Company notifying you that such expense was not made pursuant to a Company policy.

Page 3

Release of Claims.

(a)

General Release of Claims. In exchange for the consideration provided to you under this Agreement to which you would not otherwise

be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and

its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors,

insurers, affiliates, and assigns from any and all claims, liabilities, demands, causes of action, and obligations, both known and unknown,

arising from or in any way related to events, acts, conduct, or omissions occurring at any time prior to and including the date you sign

this Agreement.

(b)

Scope of Release. This general release includes, but is not limited to: (i) all claims arising from or in any way related to

your employment with the Company or the termination of that employment; (ii) all claims related to your compensation or benefits from

the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock

options, or any other ownership, equity, or profits interests in the Company; (iii) all claims for breach of contract, wrongful termination,

and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation,

emotional distress, and discharge in violation of public policy; and (v) all federal, state, and local statutory claims, including claims

for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964,

the federal Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act (“ADEA”), the California

Labor Code, the California Family Rights Act, and the California Fair Employment and Housing Act, all as amended. You acknowledge that

you have been advised, consistent with California Government Code Section 12964.5(b)(4), that you have the right to consult an attorney

regarding this Agreement and that you were given a reasonable time period of not less than five business days in which to do so. You

further acknowledge and agree that, in the event you sign this Agreement prior to the end of the reasonable time period provided by the

Company, your decision to accept such shortening of time is knowing and voluntary and is not induced by the Company through fraud, misrepresentation,

or a threat to withdraw or alter the offer prior to the expiration of the reasonable time period, or by providing different terms to employees

who sign such an agreement prior to the expiration of the time period.

(c)

ADEA Release. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA,

and that the consideration given for the waiver and releases you have given in this Agreement is in addition to anything of value to which

you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (i) your waiver and release

does not apply to any rights or claims arising after the date you sign this Agreement; (ii) you should consult with an attorney prior

to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have twenty-one (21) days to consider this Agreement

(although you may choose voluntarily to sign it sooner); (iv) you have seven (7) days following the date you sign this Agreement to revoke

this Agreement (in a written revocation sent to the Company); and (v) this Agreement will not be effective until the date upon which

the revocation period has expired, which will be the eighth day after you sign this Agreement provided that you do not revoke it (the

“Effective Date”).

Page 4

(d)

Section 1542 Waiver. In giving the release herein, which includes claims which may be unknown to you at present, you acknowledge

that you have read and understand Section 1542 of the California Civil Code, which reads as follows:

“A general release does not extend

to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release

and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”

You hereby expressly waive and relinquish all

rights and benefits under that section and any law of any other jurisdiction of similar effect with respect to your release of claims

herein, including but not limited to your release of unknown claims.

(e)

Exceptions. Notwithstanding the foregoing, you are not releasing the Company hereby from: (i) any obligation to indemnify

you pursuant to the Articles and Bylaws of the Company, any valid fully executed indemnification agreement with the Company, applicable

law, or applicable directors and officers liability insurance; (ii) any claims that cannot be waived by law; or (iii) any claims for breach

of this Agreement.

(f)

Protected Rights. You understand that nothing in this Agreement limits your ability to file a charge or complaint with the

Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health

Administration, the Department of Justice, the California Civil Rights Department, the Securities and Exchange Commission or any other

federal, state or local governmental agency or commission (“Government Agencies”). You further understand this Agreement

does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that

may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this

Agreement does not limit your right to receive a government-issued award for information provided to any Government Agency in connection

with a government whistleblower program or protected whistleblower activity, you understand and agree that, to the maximum extent permitted

by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and

any rights you have waived by signing this Agreement. Nothing in this Agreement (i) prevents you from discussing or disclosing information

about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful;

or (ii) waives any rights you may have under Section 7 of the National Labor Relations Act (subject to the release of claims set forth

herein).

Return of Company Property. You agree that, within five (5) days of the Separation

Date, you will return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control,

including, but not limited to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements,

drafts, financial and operational information, research and development information, sales and marketing information, customer lists,

prospect information, pipeline reports, sales reports, personnel information, specifications, code, software, databases, computer-recorded

information, tangible property and equipment (including, but not limited to, computing and electronic devices, mobile telephones, servers)

including those listed in Exhibit A, credit cards, entry cards, identification badges and keys, Company account and device login

and password information; and any materials of any kind which contain or embody any proprietary or confidential information of the Company

(and all reproductions or embodiments thereof in whole or in part). You agree that you will make a diligent search to locate any such

documents, property and information by the close of business on the Separation Date or as soon as possible thereafter. If you have used

any personally owned computer or other electronic device, server, or e-mail system to receive, store, review, prepare or transmit any

Company confidential or proprietary data, materials or information, within five (5) days after the Separation Date, you shall provide

the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary

information from those systems; and you agree to provide the Company access to your system as requested to verify that the necessary copying

and/or deletion is completed. Your timely compliance with this paragraph is a condition to your receipt of the Severance Benefits provided

under this Agreement.

Page 5

10.

Confidential Information Obligations. You acknowledge and reaffirm your continuing

obligations under your Employee Confidential Information and Inventions Assignment Agreement, a copy of which is attached hereto as Exhibit B

and incorporated herein by reference.

11.

Non-disparagement. Except to the extent permitted by the “Protected Rights”

Section above, you agree not to disparage the Company, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates,

and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation; provided that you

may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation.

Your continued compliance with this paragraph is a condition to your receipt of the Severance Benefits provided under this Agreement.

In addition, nothing in this provision or this Agreement prohibits or restrains you from making disclosures protected under the whistleblower

provisions of federal or state law or from exercising your rights to engage in protected speech under Section 7 of the National Labor

Relations Act, if applicable.

12.    No Voluntary Adverse Action.

You agree that you will not voluntarily (except in response to legal compulsion or as permitted under the section of this Agreement entitled

“Protected Rights”) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative

claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or

agents.

13.

Cooperation.

You agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of

any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during

the period of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company

upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and

trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation

(excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs. In addition, you agree to cooperate

fully with the Company in all matters relating to the transition of your work and responsibilities on behalf of the Company, including,

but not limited to, any present, prior or subsequent relationships and the orderly transfer of any such work and institutional knowledge

to such other persons as may be designated by the Company, by making yourself reasonably available during regular business hours.

Page 6

14.

No Admissions. You understand and agree that the promises and payments in consideration

of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person,

and that the Company makes no such admission.

15.

Representations. You hereby represent that you have: been paid all compensation

owed and for all hours worked; received all leave and leave benefits and protections for which you are eligible pursuant to the Family

and Medical Leave Act, the California Family Rights Act, or otherwise; and not suffered any on-the-job injury for which you have not already

filed a workers’ compensation claim. You further acknowledge and agree that this Agreement, and any payments or benefits provided

hereunder, are subject to any applicable recoupment, clawback, or reimbursement policy of the Company, and to any applicable law, including

in the event that the Company is required to prepare an accounting restatement or similar adjustment as a result of misconduct, noncompliance,

or facts that, if known at the time, would have constituted a breach of the foregoing representations.

16.   Tax Provisions. All payments and

benefits under this Agreement (including, without limitation, the Severance Benefits) will be subject to applicable withholding for federal,

state, foreign, provincial and local taxes. It is intended that all of the benefits and other payments payable under this Agreement satisfy,

to the greatest extent possible, an exemption from the application of Section 409A of the Internal Revenue Code of 1986, as amended, including

any applicable regulations and guidance thereunder (“Section 409A”) and this Agreement will be construed

to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement will be construed

in a manner that complies with Section 409A, and any ambiguities herein shall be interpreted accordingly. Specifically, the severance

benefits under this Agreement are intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations

Sections 1.409A-1(b)(4) and 1.409A-1(b)(9) and each installment of severance benefits, if any, is a separate “payment” for

purposes of Treasury Regulations Section 1.409A-2(b)(2)(i).

Page 7

17.

Dispute Resolution. You and the Company agree that any and all disputes, claims,

or controversies of any nature whatsoever arising from, or relating to, this Agreement or its interpretation, enforcement, breach, performance

or execution, your employment or the termination of such employment (including, but not limited to, any statutory claims), shall be resolved,

pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential

arbitration in San Diego, California (or another mutually acceptable location) conducted before a single neutral arbitrator by JAMS,

Inc. (“JAMS”) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment

Disputes (available at http://www.jamsadr.com/rules-employment-arbitration/). By agreeing to this arbitration procedure, both

you and the Company waive the right to have any claim resolved through a trial by jury or judge. You will have the right to be represented

by legal counsel at any arbitration proceeding, at your own expense. This paragraph shall not apply to any action or claim that cannot

be subject to mandatory arbitration as a matter of law, to the extent such claims are not permitted by applicable law to be submitted

to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively,

the “Excluded Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims

listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.

The arbitrator shall have sole authority for determining if a claim is subject to arbitration, and any other procedural questions related

to the dispute and bearing on the final disposition. In addition, the arbitrator shall: (a) have the authority to compel adequate discovery

for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding;

and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as

to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based.

The Company shall pay all JAMS arbitration fees. Nothing in this Agreement shall prevent you or the Company from obtaining injunctive

relief in court to prevent irreparable harm pending the conclusion of any arbitration. Any awards or orders in such arbitrations may

be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.

18.

Miscellaneous. This Agreement, including Exhibit B, constitutes the complete,

final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into

without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any

other such promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both you

and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of

both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision

of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision

of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted

by law, consistent with the intent of the parties. This Agreement will be deemed to have been entered into and will be construed and enforced

in accordance with the laws of the State of California without regard to conflict of laws principles. Any ambiguity in this Agreement

shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not

be deemed to be a waiver of any successive breach. This Agreement may be executed in counterparts and electronic or facsimile signatures

will suffice as original signatures.

[Signatures to follow on next

page]

Page 8

If this Agreement is acceptable to you, please

sign below and return the original to me. You have twenty-one (21) calendar days to decide whether to accept this Agreement, and the Company’s

offer contained herein will automatically expire if you do not sign and return it within that timeframe.

We wish you the best in your future endeavors.

Sincerely,

By:

/s/

Lindsey McClelland

VP, Head of People and Culture

I have

read, understand and agree fully to the foregoing Agreement:

/s/ Eric Hyllengren

Eric Hyllengren

April 21, 2026

Date

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Apr. 20, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 20, 2026

Entity File Number

001-40598

Entity Registrant Name

Zura Bio Limited

Entity Central Index Key

0001855644

Entity Tax Identification Number

98-1725736

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1489 W. Warm Springs Rd.

Entity Address, Address Line Two

#110

Entity Address, City or Town

Henderson

Entity Address, State or Province

Entity Address, Postal Zip Code

89014

City Area Code

702

Local Phone Number

825-9872

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A Ordinary Shares, par value $0.0001 per share

Trading Symbol

ZURA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration